Advertisement
This biological product is a unique nutriment for the brain. It helps CNS in multiple ways, regulating and improving nerve cell metabolism, promoting synapse generation, inducing nerve cell differentiation, protecting nerve cells against damages by ischemia and neurotoxins etc.
Advertisement
This clinical trial is a multicentre one, authorized by Mellow Hope and sponsored by our partner Lupin Limited which is one of the top 3 pharmaceutical companies in India. http://www.lupinworld.com. The aim of this trial is to evaluate the efficacy and safety of this product in the management of subjects with Dementia in an open labeled, prospective, phase-III clinical trial. Through this clinical trial, this product has been approved with very good efficacy and safety.
In other company news, the revised business plan under consideration as per the issuer's news announcement of yesterday September 3 2009 includes an anti-aging and cancer treatment project. More information about cancer treatment project will be shortly available with Slavica Bio Chem (Slavica) on the updated website www.Slavicabiochem.com. Slavica is a second operating subsidiary of HTDS in Serbia, Europe. The aforementioned Mellow Hope and Lupin World clinical trial and cooperation is in addition to research work of Slavica.
Mr. Terry Yuan CEO of HTDS said (sic) "With the completion of this clinical trial, we are expected to receive the registration approval for NUTRIPROTEIN within three months in India. As soon as we get the approval, we will launch this product in the local market. Without any competitors in India, we will win a large market shares."
The issuer intends to provide further updates to its shareholders from both Mellow Hope in China and Slavica Bio Chem in Serbia operations on a frequent basis including certain developments on the anti-aging and cancer treatment project which the issuer is hopeful will have a significant and positive impact on its share price and add value to its shareholders.
More details to follow shortly.
Safe Harbor Statement:
Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
CONTACT: For medical and scientific dialogue inquiry only, please contact [email protected]; For any corporate matters, please contact www.minamargroup.com/helpdesk
SOURCE Hard to Treat Diseases
